Abstract:Introduction Ketamine, a versatile anesthetic, has seen increased recreational use, leading to significant health issues, including ketamine‐induced uropathy (KIU). KIU manifests with lower urinary tract symptoms (LUTS) and can involve the upper urinary tract. This study aims to provide a comprehensive overview of KIU, addressing its pathophysiology, diagnostic strategies, and treatment options; and to define/identify future research priorities. Methods During the 2024 meeting of the International Consultation on Incontinence Research Society (ICI‐RS) in Bristol, a dedicated Proposal (P) convened to explore KIU. This initiative involved a thorough review of existing literature, expert presentations, and consensus‐driven discussions. The methodology ensured a comprehensive exploration of KIU from both clinical and pre‐clinical perspectives, leading to actionable research recommendations. Results Understanding the mechanisms of KIU is crucial for developing effective treatment options targeting specific pathophysiological pathways. Key findings include bladder fibrosis driven by transforming growth factor‐β1 (TGF‐β1), elevated purinergic responses and upregulated P2X1 purinoceptor expression, decreased barrier function due to increased expression of antiproliferative factor (APF), and functional loss of the bladder through Cav1.2 channel blockade. Research indicates that fibrosis, typically considered irreversible, may be mitigated. However, the exact timing and extent of fibrosis initiation and its impact on long‐term outcomes require further research. LUTS typically improve after ketamine cessation but relapse upon resumption, indicating a hypersensitivity mechanism involving elevated serum IgE levels. Advanced stages of KIU do not always correlate with LUTS severity, shedding light on potential systemic effects and the need for evaluating liver enzymes. Furthermore, psychological dependency on ketamine, due to its positive perceptive and mood‐altering effects, complicates cessation efforts. Long‐term management requires a holistic approach, integrating medical treatments and supportive measures to help patients navigate life with potentially irreversible complications. Conclusion This comprehensive review spans from fundamental pathology to practical clinical management, addressing both urological and systemic complications, and bridging insights from animal models to human applications. Developing effective treatment strategies necessitates addressing both the physical and psychological aspects of ketamine dependency.

Risk of Renal Function Decline in Patients with Ketamine-Associated Uropathy

Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses

Ketamine-Induced Lower Urinary Tract Symptoms: A Study of International Prostate Symptom Score and Quality of Life

Ketamine-Associated Urinary Tract Dysfunction: an Underrecognized Clinical Entity

Newer therapies and surgical management of ketamine-induced uropathy: A review

Increased Nectin-4 levels in chronic ketamine abusers and the relationship with lower urinary tract symptoms

Reduced Dorsal Prefrontal Gray Matter after Chronic Ketamine Use.

Can We Better Understand, Diagnose, and Treat Ketamine‐Induced Uropathy, and Can It Be Reversed? ICI‐RS 2024

Alterations in Regional Homogeneity of Resting-State Brain Activity in Ketamine Addicts

Lower Urinary Tract Destruction Due to Ketamine A Report of 4 Cases and Review of Literature

Long‐term ketamine administration induces bladder damage and upregulates autophagy‐associated proteins in bladder smooth muscle tissue

Widespread Reductions in Cortical Thickness Following Ketamine Abuse

Ketamine enhances autophagy and endoplasmic reticulum stress in rats and SV-HUC-1 cells via activating IRE1-TRAF2-ASK1-JNK pathway

Ketamine attenuates kidney damage and depression-like behaviors in mice with cisplatin-induced acute kidney injury

"K Cramps," Recurrent Abdominal Pain in a Patient with Chronic Ketamine Use: A Case Report

Misdiagnosis analysis for street ketamine associated urinary system dysfunction

S1860 Ketamine-Induced Cholangiopathy: A Case Series

Nephrotoxin Exposure in the 3 Years following Hospital Discharge Predicts Development or Worsening of Chronic Kidney Disease among Acute Kidney Injury Survivors

Risk factors of acute kidney injury in patients with acute heart failure

Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease

Mast cells infiltration and decreased E-cadherin expression in ketamine-induced cystitis